NCT05515315View on ClinicalTrials.gov

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2027

Conditions
Immunotherapy Esophagus Cancer
Interventions
DRUG

Tislelizumab

Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks

DRUG

Albumin paclitaxel

Participants will receive Albumin paclitaxel 260 mg/m2 , day 1 of every 3 weeks

DRUG

Nedaplatin

Participants will receive Nedaplatin 80 mg/m2 , day 1 of every 3 weeks

RADIATION

radiotherapy

50-60Gy/25-30f

Trial Locations (1)

350500

RECRUITING

Ye zai sheng, Fuzhou

All Listed Sponsors
lead

Fuzhou General Hospital

OTHER